Skip to main navigation menu Skip to main content Skip to site footer
##common.pageHeaderLogo.altText##

Narrative Review

Vol. 4 No. 1 (1998)

Treatment of Malignant Gliomas by Therapies Against Matrix Metalloproteinases

  • Charles C. Matouk, B.Sc.
  • Jamila Raja, B.Sc.
  • Voon Wee Yong, Ph.D.
  • Dylan R. Edwards, Ph.D.
  • Peter A. Forsyth, M.D., F.R.C.P.(C)
DOI
https://doi.org/10.26443/mjm.v4i1.680
Submitted
November 8, 2020
Published
2020-12-01

Abstract

N/A

References

  1. Forsyth PA, Cairncross JG. Treatment of malignant glioma in adults. Current Opinion in Neurology 8: 414-418; 1995.
  2. Canadian Cancer Statistics 1994. National Cancer Institute of Canada. Toronto, Canada; 1994.
  3. Halperin EC. Malignant gliomas in older adults with poor prognostic signs. Oncology 9: 229-234; 1995.
  4. Forsyth PA, Cairncross JG. Chemotherapy for malignant gliomas. Baillière’s Clinical Neurology 5: 371-393; 1996.
  5. Giese A, Westphal M. Glioma invasion in the central nervous system. Neurosurgery 39: 235-250; 1996
  6. Uhm JH, Dooley NP, Villemure JG, et al. Mechanisms of glioma invasion: role of matrix-metalloproteinases. Canadian Journal of Neurological Sciences 24: 3 -15; 1997.
  7. Giese A, Kluwe L, Laube B, et al. Migration of human glioma cells on myelin. Neurosurgery 38: 755-764; 1996.
  8. Scherer HJ. The forms of growth in gliomas and their practical significance. Brain 63: 1-35; 1940.
  9. Gaspar LE, Fischer BJ, MacDonald DR, et al. Supratentorial malignant glioma: patterns of recurrence and implications for external beam local treatment. International Journal of Radiation Oncology, Biology, Physics 24: 55-57; 1992.
  10. Burger PC, Dubois PJ, Schold EC, et al. Computerized tomographic and pathologic studies of the untreated, quiescent, and recurrent glioblastoma multiforme. Journal of Neurosurgery 58: 159-169; 1983.
  11. Forsyth PA, Laing TD, Gibson AW, et al. High levels of gelatinase-B and active gelatinase-A in metastatic glioblastoma. Journal of Neuro-oncology 36: 21-29; 1998.
  12. Barker FG, Israel MA. The molecular biology of brain tumors. Neurologic Clinics 13: 701-722; 1995.
  13. Coussens LM, Werb Z. Matrix metalloproteinases and the development of cancer. Chemistry and Biology 3: 895-904; 1996.
  14. Kohn EC, Liotta LA. Molecular insights into cancer invasion: strategies for prevention and intervention. Cancer Research 55: 1856-1862; 1995.
  15. Stetler-Stevenson WG, Hewitt R, Corcoran M. Matrix metalloproteinases and tumor invasion: from correlation and causality to the clinic. Seminars in Cancer Biology 7: 147-154; 1996.
  16. Liotta LA. Tumor invasion and metastasis: role of the extracellular matrix. Rhoades Memorial Award Lecture. Cancer Research 46: 1-7; 1986.
  17. Hanahan D, Folkman J. Patterns and emerging mechanisms of the angiogenic switch during tumorigenesis. Cell 86: 353-364; 1996.
  18. Corcoran ML, Kleiner DE, Stetler-Stevenson WG. Regulation of matrix metalloproteinases during extracellular matrix turnover. Advances in Experimental Medicine and Biology 385: 151-159; 1995.
  19. Murphy G, Knauper V. Relating matrix metalloproteinase structure to function: why the “hemopexin” domain? Matrix Biology 15: 511-518; 1997.
  20. Sato H, Takino T, Okada Y, et al. A matrix metalloproteinase expressed on the surface of invasive tumor cells. Nature 370: 61-65; 1994.
  21. Sato H, Okada Y, Seiki M. Membrane-type matrix metalloproteinases (MT-MMPs) in cell invasion. Thrombosis and Haemostasis 78: 497-500; 1997.
  22. Springman EB, Angleton EL, Birkedal-Hansen H, et al. Multiple modes of activation of latent human fibroblast collagenase: evidence for the role of a Cys73 active-site zinc complex in latency and a “cysteine switch” mechanism for activation. Proceedings of the National Academy of Sciences (USA) 87: 364-368; 1990.
  23. Yu AE, Hewitt RE, Kleiner DE, et al. Molecular regulation of cellular invasion — role of gelatinase A and TIMP-2. Biochemistry and Cell Biology 74: 823-31; 1996.
  24. Nagase H. Activation mechanisms of matrix metalloproteinases. Biological Chemistry 378: 151-160; 1997.
  25. Nagase H, Suzuki K, Itoh Y, et al. Involvement of tissue inhibitors of metalloproteinases (TIMPs) during matrix metalloproteinase activation. Advances in Experimental Medicine and Biology 389: 23-31; 1996.
  26. Edwards DR, Beaudry PP, Laing TD, et al. The roles of tissue inhibitors of metalloproteinases in tissue remodeling and cell growth. International Journal of Obesity 20 (Supplement 3): S9-S15; 1996.
  27. Bigg HF, Shi YE, Liu YE, et al. Specific, high affinity binding of tissue inhibitor of metalloproteinase-4 (TIMP-4) to the COOH-terminal hemopexin-like domain of human gelatinase A. Journal of Biological Chemistry 272: 15496-15500; 1997.
  28. Chambers AF, Matrisian LM. Changing views of the role of matrix metalloproteinases in metastasis. Journal of the National Cancer Institute 89: 1260-1270; 1997.
  29. Butler GS, Butler MJ, Atkinson SJ, et al. The TIMP2 membrane type 1 metalloproteinase “receptor” regulates the concentration and efficient activation of progelatinase A. Journal of Biological Chemistry 273: 871-880; 1998.
  30. Zucker S, Drews M, Conner C, et al. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). Journal of Biological Chemistry 273: 1216-1222; 1998.
  31. Liotta LA, Tryggvason K, Garbisa S, et al. Metastatic potential correlates with enzymatic degradation of basement membrane collagenase. Nature 284: 67-68; 1980.
  32. Urbanski SJ, Edwards DR, Maitland A, et al. Expression of metalloproteinases and their inhibitors in primary pulmonary carcinomas. British Journal of Cancer 66: 1188-1194; 1992.
  33. Kossakowska AE, Huchcroft SA, Urbanski SJ, et al. Comparative analysis of the expression patterns of metalloproteinases and their inhibitors in breast neoplasia, sporadic colorectal neoplasia, pulmonary carcinomas and malignant, non-Hodgkin’s lymphomas in humans. British Journal of Cancer 73: 1401-1408; 1996.
  34. Lee KS, Rha SY, Kim SJ, et al. Sequential activation and production of matrix metalloproteinase-2 during breast cancer progression. Clinical and Experimental Metastasis 14: 512-519; 1996.
  35. Takemura M, Azuma C, Kimura T, et al. Type-IV collagenase and tissue inhibitor of metalloproteinase in ovarian cancer tissues. International Journal of Gynaecology and Obstetrics 46: 303-309; 1994.
  36. Stearns M, Stearns ME. Evidence for increased activated metalloproteinase 2 (MMP-2a) expression associated with human prostate cancer progression. Oncology Research 8: 69-75; 1996.
  37. Urbanski SJ, Edwards DR, Hershfield N, et al. Expression pattern of metalloproteinases and their inhibitors changes with the progression of human sporadic colorectal neoplasia. Diagnostic Molecular Pathology 2: 81-89; 1993.
  38. Liabakk NB, Talbot I, Smith RA, et al. Matrix metalloproteinase 2 (MMP-2) and matrix metalloproteinase 9 (MMP-9) type IV collagenases in colorectal cancer. Cancer Research 56: 190-196; 1996.
  39. Nomura H, Fujimoto N, Seiki M, et al. Enhanced production of matrix metalloproteinases and activation of matrix metalloproteinase 2 (gelatinase A) in human gastric carcinomas. International Journal of Cancer 69: 9-16; 1996.
  40. Kameyama K. Expression of MMP-1 in the capsule of thyroid cancer – relationship with invasiveness. Pathology, Research and Practice 192: 20-26; 1996.
  41. Boyd DD, Nicolson GL. Mechanisms of invasion by head and neck cancers. Cancer Treatment and Research 74: 117-130; 1995.
  42. Barille S, Akhoundi C, Collette M, et al. Metalloproteinases in multiple myeloma: production of matrix metalloproteinase-9 (MMP-9), activation of proMMP-2, and induction of MMP-1 by myeloma cells. Blood 90: 1649-1655; 1997.
  43. Kossakowska AE, Urbanski SJ, Watson A, et al. Patterns of expression of metalloproteinases and their inhibitors in human malignant lymphomas. Oncology Research 5: 19-28; 1993.
  44. Kossakowska AE, Urbanski SJ, Huchcroft SA, et al.Relationship between the clinical aggressiveness of large cell immunoblastic lymphomas and expression of 92 kDa gelatinase (type IV collagenase) and tissue inhibitor of metalloproteinases-1 (TIMP-1) RNAs. Oncology Research. 4: 233-240; 1992.
  45. Kossakowska AE, Urbanski SJ, Edwards DR. Tissue inhibitor of metalloproteinases-1 (TIMP-1) RNA is expressed at elevated levels in malignant non-Hodgkin’s lymphomas. Blood 77: 2475- 2481; 1991.
  46. Ismair MG, Ries C, Petrides PE. Matrix metalloproteinases and their inhibitors in acute myeloid leukemia. Leukemia 11 (Supplement): 527-529; 1997.
  47. Yong VW, Krekoski CA, Forsyth PA, et al. Matrix metalloproteinases and diseases of the CNS. Trends in Neurosciences 21: 75-80; 1997.
  48. Rao JS, Steck PA, Mohanam S, et al. Elevated levels of Mr 92,000 type IV collagenase in human brain tumors. Cancer Research 53: 2208-2211; 1993.
  49. Saxena A, Robertson JT, Kufta C, et al. Increased expression of gelatinase A and TIMP-2 in primary human glioblastomas. International Journal of Oncology 7: 469-473; 1995.
  50. Sawaya RE, Yamamoto M, Gokaslan ZL, et al. Expression and localization of 72 kDa type IV collagenase (MMP-2) in human malignant gliomas in vivo. Clinical and Experimental Metastasis 14: 35-42; 1996.
  51. Costello PC, Del Maestro RF, Stetler-Stevenson WG. Gelatinase A expression in human malignant gliomas. Annals of the New York Academy of Sciences 732: 450-452; 1994.
  52. Nakagawa, T, Kubota T, Kabuto M, et al. Production of matrix metalloproteinases and tissue inhibitor of metalloproteinases-1 by human brain tumors. Journal of Neurosurgery 81: 69-77; 1994.
  53. Rutka JT, Matsuzawa K, Hubbard SL, et al. Expression of TIMP-1, TIMP-2, 72- and 92-kDa type IV collagenase transcripts in human astrocytoma cell lines: correlation with astrocytoma cell invasiveness. International Journal of Oncology 6: 877-844; 1995.
  54. Forsyth PA, Wong H, Laing TD, et al. Survey of gelatinase-A and -B and MT1-MMP in gliomas. Submitted.
  55. Uhm JH, Dooley NP, Villemure J-G, et al. Glioma invasion in vitro: regulation of matrix metalloprotease-2 and protein kinase C. Clinical and Experimental Metastasis 14: 421-433; 1996.
  56. Yamamoto M, Mohanam S, Sawaya R, et al. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Research 56: 384-392; 1996.
  57. Yamada T, Yoshiyama Y, Sato H, et al. White matter microglia produce membrane-type matrix metalloprotease, an activator of gelatinase A, in human brain tissues. Acta Neuropathologica 90: 421-424; 1995.
  58. Mohanam S, Chintala SK, Go Y, et al. In vitro inhibition of human glioblastoma cell line invasiveness by antisense uPA receptor. Oncogene 14: 1351-1359; 1997.
  59. Folkman J. What is the evidence that tumors are angiogenesis dependent? Journal of the National Cancer Institute 82: 4-6; 1990.
  60. Brown PD, Giavazzi R. Matrix metalloproteinase inhibition: a review of anti-tumor activity. Annals of Oncology 6: 967-974; 1995.
  61. Wojtowicz-Praga SM, Dickson RB, Hawkins MJ. Matrix metalloproteinase inhibitors. Investigational New Drugs 15: 61- 75; 1997.
  62. Davies B, Brown PD, East N, et al. A synthetic matrix metalloproteinase inhibitor decreases tumor burden and prolongs survival of mice bearing human ovarian carcinoma xenografts. Cancer Research. 53: 2087-2091; 1993.
  63. Watson SA, Morris TM, Crosbee DM, et al. Inhibition of organ invasion by the matrix metalloproteinase inhibitor, batimastat (BB-94), in two human colorectal carcinoma metastasis models. Cancer Research 55: 3629-3633; 1995.
  64. Wang X, Fu X, Brown PD, et al. Matrix metalloproteinase inhibitor BB-94 (batimastat) inhibits human colon tumor growth and spread in a patient-like orthotopic model in nude mice. Cancer Research 54: 4726-4728; 1994.
  65. Taraboletti G, Garofalo A, Belotti D, et al. Inhibition of angiogenesis and murine hemangioma growth by batimastat, a synthetic inhibitor of matrix metalloproteinases. Journal of the National Cancer Institute 87: 293-298; 1995.
  66. Beattie GJ, Young HA, Smyth JF. Phase I study of intra-peritoneal metalloproteinase inhibitor BB-94 in patients with malignant ascites. Abstract presented at the 8th NCI-EORTC Symposium of New Drug Development, Amsterdam; March 1994.
  67. Macaulay VM, O’Byrne KJ, Saunders MP, et al. Phase I study of matrix metalloproteinase (MMP) inhibitor batimastat (BB-94) in patients with malignant pleural effusions. British Journal of Cancer 71(Supplement XXIV): 11; 1995.
  68. Leppert D, Waubant E, Galardy R, et al. T cell gelatinases mediate basement membrane transmigration in vitro. Journal of Immunology 154: 4379-4389; 1995.
  69. Brown PD. Synthetic matrix metalloproteinase inhibitors: from cancer models to cancer patients. Proceedings of the American Association of Cancer Research 37: 633-334; 1996.
  70. Hayashi T, Stetler-Stevenson WG, Fleming MV, et al. Immunohistochemical study of metalloproteinases and their tissue inhibitors in the lungs of patients with diffuse alveolar damage and idiopathic pulmonary fibrosis. American Journal of Pathology 149: 1241-1256; 1996.
  71. Hayashi T, Fleming MV, Stetler-Stevenson WG, et al. Immunohistochemical study of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) in pulmonary lymphangioleiomyomatosis (LAM). Human Pathology 28: 1071-1078; 1997.
  72. Tamarina NA, McMillan WD, Shively VP, et al. Expression of matrix metalloproteinases and their inhibitors in aneurysms and normal aorta. Surgery 122: 264-271; 1997.
  73. Galis ZS, Sukhova GK, Lark MW, et al. Increased expression of matrix metalloproteinases and matrix degrading activity in vulnerable regions of human atherosclerotic plaques. Journal of Clinical Investigation 94: 2493-2503; 1994.
  74. Vaalamo M, Matilla L, Johansson N, et al. Distinct populations of stromal cells express collagenase-3 (MMP-13) and collagenase-1 (MMP-1) in chronic ulcers but not in normally healing wounds. Journal of Investigative Dermatology 109: 96-101; 1997.
  75. Akiyama K, Shikata K, Sugimoto H, et al. Changes in serum concentrations of matrix metalloproteinases, tissue inhibitors of metalloproteinases and type IV collagen in patients with various types of glomerulonephritis. Research Communications in Molecular Pathology and Pharmacology. 95: 115-128; 1997.
  76. Price A, Raja JB, Rewcastle NB, et al. Marked inhibiion of tumour growth in a malignant glioma tumor model by the novel synthetic matrix metalloproteinase inhibitor AG3340. Proceedings of the 89th Annual Meeting of the American Association for Cancer Research 39: 301-302; 1998.

Downloads

Download data is not yet available.